Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
Open Access
- 11 July 2026
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 56 (11) , 1614-1631
Abstract
Background and Aim: Although nucleos(t)ide analog (NUC) therapy reduces hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients, HCC can develop despite viral suppression. Identifying predictive biomarkers of HCC during NUC therapy remains clinically important. This study aimed to identify novel biomarkers by proteomic analysis of serum extracellular vesicle (EV) proteins in CHB patients receiving NUC therapy. Methods: We enrolled 242 CHB patients treated with NUCs for over one year, with serum HBV DNA < 3.0 log IU/mL, no prior HCC, and available stored serum samples. Proteomic analysis of serum EV proteins was carried out to identify candidate biomarkers, followed by validation of their serum levels using enzyme‐linked immunosorbent assay (ELISA). Results: The median age was 55 years; 144 were male. During a median follow‐up of 10.1 years, 44 patients (18.2%) developed HCC. Five candidate EV proteins were identified: fibulin‐3, VCAM‐1, fibronectin, vWF, and FGFBP2. In univariate Cox analysis of serum levels of candidate EV proteins measured by ELISA, fibulin‐3 and VCAM‐1 were identified as significant predictive factors. In multivariate analysis, male sex, GGT, AFP, fibulin‐3, and the FIB‐4 index were independent predictors, whereas VCAM‐1 was not. A cutoff value for fibulin‐3 was set at 10.8 μg/mL. HCC incidence was significantly higher in patients with fibulin‐3 ≥ 10.8 μg/mL and in those with ≥ 3 of five identified risk factors. The 10‐year cumulative HCC incidence was 0% versus 37.2% in patients with 0 versus ≥ 3 risk factors. Conclusion: Serum fibulin‐3 is a novel biomarker predictive of HCC in CHB patients undergoing NUC therapy.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP25fk0310534)
This publication has 48 references indexed in Scilit:
- Comprehensive proteomic profiling of plasma and serum phosphatidylserine-positive extracellular vesicles reveals tissue-specific proteinsiScience, 2022
- Descriptive analysis of Fibulin-3 and the extracellular vesicle marker, Alix, in drusen from a small cohort of postmortem human eyesExperimental Eye Research, 2021
- Epidermal growth factor‐containing fibulin‐like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B)Cancer Medicine, 2019
- Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapyJournal of Hepatology, 2018
- Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infectionJournal of Hepatology, 2017
- PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyJournal of Hepatology, 2016
- Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirJournal of Hepatology, 2015
- Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discoveryProteomics, 2010
- External validation of FIB-4: Diagnostic accuracy is limited in elderly populationsHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006